Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Azenta Reports Second Quarter Results for Fiscal 2026, Ended March 31, 2026, Updates Full Year Fiscal 2026 Guidance, and Extends Long-Range Plan to 2029

      Azenta logo (PRNewsfoto/Azenta)

      News provided by

      Azenta

      May 05, 2026, 16:30 ET

      Share this article

      Share this article


      • FY'26 total reported revenue from continuing operations to range between approximately $603 to $621 million
      • FY'26 organic revenue is now expected to range from down approximately 2% to up 1%, compared to prior guidance of 3% to 5% growth
      • FY'26 Adjusted EBITDA margin is now expected to range from down approximately 125 basis points to flat, compared to prior expectations of approximately 300 basis points of expansion
      • Long-range plan timing updated to 2029 versus 2028 before in connection with revised 2026 guidance. Market opportunities, strategic priorities, and value creation framework remain intact.

      BURLINGTON, Mass., May 5, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the second quarter ended March 31, 2026.



      The results of B Medical Systems are treated as discontinued operations and reflected in total diluted EPS, following the
      Company
      's announcement in the first fiscal quarter of 2025 of its intention to pursue a sale and the entry into a definitive
      agreement to sell the business.




      Quarter Ended

      Dollars in millions, except per share data


      March 31,


      December 31,


      March 31,


      Change



      2026


      2025


      2025(1)


      Prior Qtr


      Prior Yr.

      Revenue from Continuing Operations


      $       145


      $          149


      $     143


      (3) %


      1 %

      Organic growth










      (3) %

      Sample Management Solutions


      $         81


      $            81


      $       80


      (0) %


      2 %

      Multiomics


      $         64


      $            67


      $       64


      (5) %


      0 %












      Diluted EPS Continuing Operations


      $     (3.41)


      $        (0.11)


      $   (0.43)


      NM


      NM

      Diluted EPS Total


      $     (3.49)


      $        (0.34)


      $   (1.04)


      NM


      NM












      Non-GAAP Diluted EPS Continuing Operations


      $     (0.04)


      $         0.09


      $    0.01


      NM


      NM

      Adjusted EBITDA - Continuing Operations


      $           8


      $            13


      $       12


      (39) %


      (36) %

      Adjusted EBITDA Margin - Continuing Operations


      5.4 %


      8.5 %


      8.5 %






      (1)   Reflects revisions for an immaterial classification error among cost of revenue, research and development expenses,
            and selling, general and administrative expenses, and other immaterial adjustments, as further described in the Annual
            Report on Form 10-K for the fiscal year ended September 30, 2025.


      Management Comments
      "Our second quarter results fell short of our expectations, reflecting both execution gaps and a more cautious demand environment, particularly in North America," said John Marotta, President and CEO of Azenta Life Sciences. "As a result, we have revised our fiscal 2026 outlook and taken decisive actions to strengthen execution, reinforce operational discipline, and improve visibility across the business. At the same time, we saw areas of resilience, including continued growth in Sample Repository Solutions and Consumables and Instruments, reinforcing the strength of our recurring revenue offerings.

      In 2026, our priority is the transformation of our Multiomics business, with a focus on strengthening commercial execution, optimizing our operating footprint, and improving productivity through Azenta Business System. We have strengthened leadership and are increasing operational rigor to drive greater accountability and consistency across the organization.

      Given the updated 2026 outlook, we are extending the timeline of our long‑range plan targets from 2028 to 2029. This reflects a disciplined and prudent approach to execution in the current environment and, while postponing achievement of the financial targets, does not change our confidence in our strategy. While near‑term conditions remain measured, we continue to see a compelling long‑term market opportunity and believe the actions underway position Azenta for improved execution, greater consistency, and profitable long‑term value creation."

      Second Quarter Fiscal 2026 Results - Continuing Operations

      • Revenue was $145 million, up 1% year over year. Organic revenue, which excludes a 3-percentage point impact from foreign exchange and a 1-percentage point from the acquisition of UK Biocentre Limited, declined 3% year over year, reflecting lower revenue in Multiomics and in Sample Management Solutions.
      • Sample Management Solutions revenue was $81 million, up 2% over year.
        • Organic revenue, which excludes the impact from foreign exchange and the contribution from the acquisition of UK Biocentre Limited, declined 3%, mainly driven by lower revenue in Core Products, particularly in Automated Stores and Cryogenic Systems, partially offset by higher revenue in Sample Repository Solutions, Product Services and Consumables and Instruments.
      • Multiomics revenue was $64 million, flat year over year.
        • Organic revenue, which excludes the impact from foreign exchange, was down 2% year over year, primarily driven by lower Sanger Sequencing revenue, partially offset by higher revenue in Next Generation Sequencing and Gene Synthesis.

      Summary of GAAP Earnings Results - Continuing Operations

      • Operating loss was $165.8 million. Operating margin was (114.5%), down 102% year over year.
        • Gross margin was 42.8%, down 96 basis points year over year, driven by lower fixed-cost absorption from reduced volumes in North America, as well as costs related to Automated Stores rework, and an increase in inventory reserves recorded during the period.
        • Operating expenses in the quarter were $228 million, up 181% year-over-year, primarily driven by a non-cash goodwill impairment charge of $149 million. The increase also reflects higher research and development expenses, partially offset by lower selling, general and administrative expenses and lower restructuring charges.
      • Total other income included $4 million of net interest income and $4 million gain related to the non-cash settlement of a preexisting contractual relationship with UK Biocentre Limited, versus $4 million and $1 million, respectively, in the prior year period.
      • Diluted EPS from continuing operations was ($3.41) compared to ($0.43) in the second quarter of fiscal year 2025. Diluted EPS from discontinued operations was ($0.08), compared to ($0.61) a year ago. Total diluted EPS was ($3.49), compared to ($1.04) a year ago.

      Summary of Non-GAAP Earnings Results - Continuing Operations

      • Adjusted operating loss was $7.0 million. Adjusted operating margin was (4.9%), a decrease of 300  basis points year over year.
        • Adjusted gross margin was 44.3%, down 110 basis points compared to the second quarter of fiscal 2025, driven by lower fixed-cost absorption from reduced volumes in North America, costs related to Automated Stores rework, and an increase in inventory reserves recorded during the period.
        • Adjusted operating expenses in the quarter were $71 million, up 5% year over year, driven by higher research and development costs and higher selling, general and administrative expenses.
      • Adjusted EBITDA was $7.8 million, and Adjusted EBITDA margin was 5.4%, a decrease of 320 basis points year over year.
      • Non-GAAP Diluted EPS was ($0.04), compared to $0.01 one year ago.

      Cash and Liquidity as of March 31, 2026

      • The Company ended the quarter with a total balance of cash, cash equivalents, restricted cash and marketable securities of $565 million.
      • Operating cash flow was $12 million in the quarter. Capital expenditures were $7 million, and free cash flow (cash flow from operations less capital expenditures) was $5 million.

      Share Repurchase Program Update

      • On December 8, 2025, our Board of Directors approved a share repurchase program authorizing the repurchase of up to $250 million of our common stock through December 31, 2028, or the 2025 Repurchase Program. Repurchases under the 2025 Repurchase Program may be made in the open market or through privately negotiated transactions (including under an accelerated share repurchase agreement), or by other means, including through the use of trading plans intended to qualify under Rule 10b5-1 under the Exchange Act, subject to market and business conditions, legal requirements, and other factors. We are not obligated to acquire any particular amount of common stock under the 2025 Repurchase Program, and share repurchases may be commenced or suspended at any time at our discretion. As of the date of this press release , there have been no repurchases under the 2025 Repurchase Program.

      Updated Fiscal 2026 Guidance – Continuing Operations

      • The Company now expects total reported revenue from continuing operations to range between approximately $603 to $621 million for the fiscal year ending September 30, 2026.
      • Total organic revenue, which excludes the impact of foreign exchange and the contribution from the acquisition of UK Biocentre Limited, is now expected to range between down approximately 2% to up 1% relative to fiscal 2025, compared to prior guidance of 3% to 5% growth.
        • Organic revenue for Sample Management Solutions is now expected to grow approximately low-single-digits, versus prior expectations of mid-single-digit growth.
        • Organic revenue for Multiomics is now expected to decline approximately mid-single-digits, versus prior expectations of low-single-digit growth.
      • Adjusted EBITDA margin is now expected to decline in a range of approximately 125 basis points to flat relative to fiscal 2025, compared to prior expectations of approximately 300 basis points expansion. This outlook excludes an expected dilution of approximately 35 basis points from the UK Biocentre acquisition.
      • Free Cash flow (cash flow from operations less capital expenditures) is now expected to improve approximately 10% to 15% year-over-year, compared to prior expectations of approximately 30% improvement.

      Long-Range Plan Update

      • In connection with the revised 2026 outlook, the Company is extending the timeline of its long-range plan by one year, from 2028 to 2029. The Company continues to believe in the strength of its market opportunities, strategic priorities, and long-term value creation framework.

      Sale of B Medical Systems

      • On December 23, 2025, we entered into a definitive Sale and Purchase Agreement with Thelema S.À R.L. for the sale of B Medical Systems business, for a purchase price of $63 million. As previously disclosed, the transaction was expected to close on or before March 31, 2026, subject to the satisfaction of customary closing conditions, including the buyer securing required financing. On March 27, 2026, the Company was informed by Thelema that it has not yet secured the financing required to complete the transaction and, as a result, the transaction did not close by March 31, 2026. Thelema has indicated that it requires additional time to complete its financing arrangements. The transaction remains subject to the satisfaction of all closing conditions, including the buyer securing the required financing, and there can be no assurance that the transaction will be completed on a revised timeline or at all. The parties have not amended or terminated the agreement as of the date of this press release.

      Azenta does not provide forward-looking guidance on a GAAP basis for the measures on which it provides forward-looking non-GAAP guidance as the Company is unable to provide a quantitative reconciliation of forward-looking non-GAAP measures to the most directly comparable forward-looking GAAP measure, without unreasonable effort, because of the inherent difficulty in accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliations that have not yet occurred, are dependent on various factors, are out of the company's control, or cannot be reasonably predicted. Such adjustments include, but are not limited to, transformation costs, restructuring charges, costs related to acquisitions and divestitures costs, governance-related matters, goodwill and intangible impairments, stock-based compensation, and other gains and charges that are not representative of the normal operations of the business.

      Conference Call and Webcast
      Azenta management will webcast its second quarter fiscal 2026 earnings conference call on May 06, 2026 at 8:30 a.m. Eastern Time. During the call, Company management will respond to questions concerning, but not limited to, the Company's financial performance, business conditions and industry outlook. Management's responses could contain information that has not been previously disclosed.

      The call will be broadcast live over the Internet and, together with presentation materials and supplemental information referenced on the call, will be hosted at the Investor Relations section of Azenta's website at https://investors.azenta.com/events. The supplemental information is being posted at the time of this earnings release, and the presentation materials will be posted ahead of the earnings call. A replay of the webcast will be archived on the website for convenient on-demand access.

      Regulation G – Use of Non-GAAP financial Measures
      The Company supplements its GAAP financial measures with certain non-GAAP financial measures to provide investors a better perspective on the results of business operations, which the Company believes is more comparable to the similar analyses provided by its peers. These measures are not presented in accordance with, nor are they a substitute for, U.S. generally accepted accounting principles, or GAAP. These measures should always be considered in conjunction with appropriate GAAP measures. A reconciliation of non-GAAP measures to the most nearly comparable GAAP measures is included at the end of this release following the consolidated balance sheets and statements of operations. Certain amounts in the tables that supplement the consolidated financial statements may not sum due to rounding. All percentages are calculated using unrounded amounts.

      "Safe Harbor Statement" under Section 21E of the Securities Exchange Act of 1934
      Some statements in this release are forward-looking statements made under Section 21E of the Securities Exchange Act of 1934. These statements are neither promises nor guarantees but involve risks and uncertainties, both known and unknown, that could cause Azenta's actual financial and business results to differ materially from those expressed or implied by such statements. They are based on the facts and assumptions known to management at the time they are made. Forward looking statements include, but are not limited to, statements regarding the Company's guidance and outlook for fiscal year 2026, including revenue, organic revenue growth, earnings, Adjusted EBITDA margin and free cash flow expectations; expectations regarding the timing, execution and benefits of operational, commercial and organizational transformation initiatives; anticipated productivity improvements and cost actions; expectations regarding demand trends and end market conditions; statements regarding the Company's long range plan and multi-year financial targets, including the extension of the long range plan timeline to 2029.

      Factors that could cause actual results to differ materially from those expressed or implied by forward looking statements include, but are not limited to: the Company's ability to execute on and realize the expected benefits from its transformation and operational improvement initiatives; changes in customer demand, purchasing behavior or funding conditions in the markets the Company serves; macroeconomic, geopolitical or regulatory developments; the impact of foreign currency fluctuations; the Company's ability to effectively manage costs, improve productivity and achieve anticipated margin improvements; supply chain disruptions; competitive dynamics; the ability of customers to meet payment obligations; uncertainty regarding the timing or completion of the B Medical Systems divestiture; and other risks and uncertainties described in the Company's filings with the Securities and Exchange Commission, including but not limited to its Annual Report on Form 10 K, Quarterly Reports on Form 10 Q and Current Reports on Form 8 K. Because forward looking statements relate to future events and are based on current expectations, they are inherently subject to significant uncertainties, particularly with respect to projections and assumptions extending over multiple years. As a result, actual outcomes may differ materially from those projected.

      Azenta expressly disclaims any obligation or undertaking to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

      About Azenta Life Sciences
       Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling life science organizations around the world to bring impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. Our global team delivers and supports these products and services through our industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey.

      Azenta is headquartered in Burlington, Massachusetts, with operations in North America, Europe, and Asia. For more information, please visit www.azenta.com.

      AZENTA INVESTOR CONTACTS:

      Yvonne Perron
      Vice President, Financial Planning & Analysis and Investor Relations
      [email protected]

      Maria Isabel Cuartas
      Manager Investor Relations
      [email protected]

      AZENTA, INC.

      CONSOLIDATED STATEMENTS OF OPERATIONS

      (unaudited)

      (In thousands, except per share data)



      Three Months Ended

      March 31,


      Six Months Ended

      March 31,


      2026


      2025


      2026


      2025

      Revenue








      Products

      $       37,642


      $       41,955


      $       78,726


      $       85,782

      Services

      107,153


      101,383


      214,711


      204,992

      Total revenue

      144,795


      143,338


      293,437


      290,774

      Cost of revenue








      Products

      22,122


      24,994


      46,871


      49,035

      Services

      60,638


      55,561


      120,825


      110,137

      Total cost of revenue

      82,760


      80,555


      167,696


      159,172

      Gross profit

      62,035


      62,783


      125,741


      131,602

      Operating expenses








      Research and development

      9,433


      7,602


      18,622


      14,715

      Selling, general and administrative

      67,887


      69,795


      128,498


      139,771

      Impairment of goodwill and intangible assets

      149,083


      —


      149,083


      —

      Restructuring charges

      1,422


      3,580


      2,565


      4,011

      Total operating expenses

      227,825


      80,977


      298,768


      158,497

      Operating loss

      (165,790)


      (18,194)


      (173,027)


      (26,895)

      Other income








      Interest income, net

      4,387


      4,489


      9,485


      8,787

      Other income, net

      4,059


      1,158


      4,138


      2,362

      Loss from continuing operations before
      income taxes

      (157,344)


      (12,547)


      (159,404)


      (15,746)

      Income tax (benefit) expense

      (323)


      7,243


      2,807


      11,117

      Loss from continuing operations

      (157,021)


      (19,790)


      (162,211)


      (26,863)

      Loss from discontinued operations, net of tax

      (3,777)


      (27,871)


      (14,019)


      (31,790)

      Net loss

      $   (160,798)


      $     (47,661)


      $   (176,230)


      $     (58,653)

      Basic net loss per share:








      Loss from continuing operations

      $         (3.41)


      $         (0.43)


      $         (3.53)


      $         (0.59)

      Loss from discontinued operations, net of tax

      $         (0.08)


      $         (0.61)


      $         (0.30)


      $         (0.70)

      Basic net loss per share

      $         (3.49)


      $         (1.04)


      $         (3.83)


      $         (1.29)

      Diluted net loss per share:








      Loss from continuing operations

      $         (3.41)


      $         (0.43)


      $         (3.53)


      $         (0.59)

      Loss from discontinued operations, net of tax

      $         (0.08)


      $         (0.61)


      $         (0.30)


      $         (0.70)

      Diluted net loss per share

      $         (3.49)


      $         (1.04)


      $         (3.83)


      $         (1.29)

      Weighted average shares used in computing net
      loss per share:








      Basic

      46,063


      45,732


      45,995


      45,658

      Diluted

      46,063


      45,732


      45,995


      45,658

      AZENTA, INC.

      CONSOLIDATED BALANCE SHEETS

      (unaudited)

      (In thousands, except share and per share data)



      March 31,


      September 30,





      Assets




      Current assets




      Cash and cash equivalents

      $        234,033


      $        279,783

      Short-term marketable securities

      146,484


      61,137

      Accounts receivable, net of allowance for expected credit losses ($4,481and $4,649,
      respectively)

      131,318


      142,181

      Inventories

      78,510


      74,956

      Short-term restricted cash

      2,410


      2,359

      Refundable income taxes

      6,838


      9,728

      Prepaid expenses and other current assets

      50,214


      64,660

      Current assets held for sale

      77,178


      73,535

      Total current assets

      726,985


      708,339

      Property, plant and equipment, net

      171,832


      153,954

      Long-term marketable securities

      177,831


      201,585

      Long-term deferred tax assets

      501


      726

      Operating lease right-of-use assets

      59,451


      54,048

      Goodwill

      552,396


      702,395

      Intangible assets, net

      92,107


      101,814

      Long-term income taxes receivable

      45,600


      45,600

      Other assets

      8,814


      6,115

      Noncurrent assets held for sale

      68,372


      85,006

      Total assets

      $     1,903,889


      $     2,059,582

      Liabilities and stockholders' equity




      Current liabilities




      Accounts payable

      $          33,136


      $          37,722

      Deferred revenue

      39,013


      31,569

      Derivative liability

      29,615


      33,420

      Accrued warranty and retrofit costs

      4,157


      4,713

      Accrued compensation and benefits

      29,146


      35,799

      Accrued customer deposits

      36,217


      26,499

      Accrued income taxes payable

      8,753


      9,416

      Accrued expenses and other current liabilities

      45,739


      30,268

      Current liabilities held for sale

      31,416


      28,268

      Total current liabilities

      257,192


      237,674

      Long-term deferred tax liabilities

      15,747


      18,245

      Long-term operating lease liabilities

      55,711


      51,244

      Other long-term liabilities

      10,892


      11,142

      Noncurrent liabilities held for sale

      9,670


      14,291

      Total liabilities

      349,212


      332,596





      Stockholders' equity




      Preferred stock, $0.01 par value - 1,000,000 shares authorized, no shares issued or outstanding

      —


      —

      Common stock, $0.01 par value - 125,000,000 shares authorized, 59,553,293 shares issued and
      46,091,424 shares outstanding at March 31, 2026; 59,320,848 shares issued and 45,858,979
      shares outstanding at September 30, 2025

      596


      594

      Additional paid-in capital

      538,782


      529,605

      Accumulated other comprehensive loss

      (27,471)


      (22,213)

      Treasury stock, at cost - 13,461,869 shares at March 31, 2026 and September 30, 2025

      (200,956)


      (200,956)

      Retained earnings

      1,243,726


      1,419,956

      Total stockholders' equity

      1,554,677


      1,726,986

      Total liabilities and stockholders' equity

      $     1,903,889


      $     2,059,582

      AZENTA, INC.

      CONSOLIDATED STATEMENTS OF CASH FLOWS

      (unaudited)

      (In thousands)



      Six Months Ended March 31,


      2026


      2025

      Cash flows from operating activities




      Net loss

      $      (176,230)


      $       (58,653)

      Adjustments to reconcile net loss to net cash provided by operating activities:




      Depreciation and amortization

      27,650


      32,053

      Impairment of goodwill and intangible assets

      149,083


      —

      Non-cash gain from settlement of preexisting contractual relationship

      (3,858)


      —

      Loss on assets held for sale

      15,965


      31,848

      Inventory write-downs and other asset write-offs

      1,883


      4,326

      Stock-based compensation

      10,420


      13,453

      Amortization and accretion on marketable securities

      (682)


      (983)

      Deferred income taxes

      (5,298)


      (4,183)

      Loss (gain) on disposals of property, plant and equipment

      19


      (7)

      Changes in operating assets and liabilities:




      Accounts receivable

      8,541


      6,713

      Inventories

      (6,700)


      (5,780)

      Accounts payable

      (4,380)


      1,981

      Deferred revenue

      7,141


      12,042

      Accrued warranty and retrofit costs

      (122)


      343

      Accrued compensation and tax withholdings

      (6,245)


      (1,956)

      Accrued restructuring costs

      506


      1,547

      Other assets and liabilities

      15,338


      11,457

      Net cash provided by operating activities

      33,031


      44,201

      Cash flows from investing activities




      Purchases of property, plant and equipment

      (13,595)


      (15,158)

      Purchases of marketable securities

      (328,835)


      (236,237)

      Sales and maturities of marketable securities

      266,470


      184,636

      Acquisition of UK Biocentre, net of cash acquired

      (9,688)


      —

      Proceeds from other investment

      —


      2,130

      Net investment hedge settlement

      —


      3,043

      Deposit received for the sale of B Medical Systems business

      9,000


      —

      Net cash used in investing activities

      (76,648)


      (61,586)

      Cash flows from financing activities




      Proceeds from issuance of common stock

      1,179


      1,553

      Payments of finance leases

      (411)


      (457)

      Withholding tax payments on net share settlements on equity awards

      (2,420)


      —

      Excise tax payment for settled share repurchases

      —


      (11,376)

      Net cash used in financing activities

      (1,652)


      (10,280)

      Effects of exchange rate changes on cash, cash equivalents and restricted cash

      (2,128)


      (4,459)

      Net decrease in cash, cash equivalents and restricted cash

      (47,397)


      (32,124)

      Cash, cash equivalents and restricted cash, beginning of period

      296,685


      320,990

      Cash, cash equivalents and restricted cash, end of period

      $       249,288


      $      288,866

      Supplemental disclosures:




      Cash paid / (received) for income taxes, net

      $           3,466


      $         (4,594)

      Purchases of property, plant and equipment included in accounts payable and
      accrued expenses

      $           5,296


      $          5,773


      Reconciliation of cash, cash equivalents and restricted cash to the condensed
      consolidated balance sheets





      March 31,
      2026


      September 30,
      2025

      Cash and cash equivalents of continuing operations

      $       234,033


      $      279,783

      Cash included in current assets held for sale

      8,763


      13,206

      Short-term restricted cash

      2,410


      2,359

      Long-term restricted cash included in other assets

      4,082


      1,337

      Total cash, cash equivalents and restricted cash shown in the condensed
      consolidated statements of cash flows

      $       249,288


      $       296,685

      Notes on Non-GAAP Financial Measures - Continuing Operations
      Non-GAAP financial measures are used in addition to and in conjunction with results presented in accordance with GAAP and should not be relied upon to the exclusion of GAAP financial measures. Management adjusts the GAAP results for the impact of amortization of intangible assets, restructuring charges, purchase price accounting adjustments and charges related to M&A, non-recurring costs related to the Company's business transformation initiatives and share repurchases to provide investors better perspective on the results of operations which the Company believes is more comparable to the similar analysis provided by its peers. Management also excludes special charges and gains, such as impairment losses, gains and losses from the sale of assets, certain tax benefits and charges, as well as other gains and charges that are not representative of the normal operations of the business. Management strongly encourages investors to review our financial statements and publicly filed reports in their entirety and not rely on any single measure.


      Quarter Ended


      March 31, 2026


      December 31, 2025


      March 31, 2025(*)

      Amounts in thousands, except
      per share data

      $


      per
      diluted
      share


      $


      per
      diluted
      share


      $


      per
      diluted
      share

      Net loss from continuing
      operations

      $ (157,021)


      $     (3.41)


      $  (5,190)


      $      (0.11)


      $ (19,790)


      $      (0.43)

      Adjustments:












      Amortization of completed
      technology

      2,076


      0.05


      1,860


      0.04


      2,308


      0.05

      Amortization of other
      intangible assets

      3,563


      0.08


      3,551


      0.08


      3,803


      0.08

      Transformation costs(1)

      440


      0.01


      1,202


      0.03


      5,183


      0.11

      Restructuring charges

      1,422


      0.03


      1,143


      0.02


      3,580


      0.08

      Impairment of goodwill and
      intangible assets(2)

      149,083


      3.24


      —


      —


      —


      —

      Merger and acquisition costs(3)

      2,175


      0.05


      13


      0.00


      688


      0.02

      Non-recurring other income(4)

      (3,858)


      (0.08)


      —


      —


      (2,130)


      (0.05)

      Tax adjustments(5)

      —


      —


      —


      —


      6,900


      0.15

      Tax effect of adjustments

      331


      0.01


      1,570


      0.03


      98


      0.00

      Other adjustments

      13


      0.00


      13


      0.00


      (17)


      0.00

      Non-GAAP adjusted net
      income (loss) from
      continuing operations

      $     (1,776)


      $      (0.04)


      $   4,162


      $       0.09


      $       623


      $       0.01

      Stock-based compensation,
           pre-tax

      6,268


      0.14


      3,862


      0.08


      8,031


      0.18

      Tax rate

      13 %


      —


      13 %


      —


      17 %


      —

      Stock-based compensation,
      net of tax

      5,453


      0.12


      3,360


      0.07


      6,690


      0.15

      Non-GAAP adjusted net income
      excluding stock-based
      compensation - continuing
      operations

      $      3,677


      $       0.08


      $   7,522


      $       0.16


      $    7,313


      $       0.16













      Shares used in computing
      non-GAAP diluted net income
      per share



      46,063




      45,929




      45,732


      Six Months Ended


      March 31, 2026


      March 31, 2025(*)

      Amounts in thousands, except per share data

      $


      per
      diluted
      share


      $


      per
      diluted
      share

      Net loss from continuing operations

      $    (162,211)


      $          (3.53)


      $    (26,863)


      $          (0.59)

      Adjustments:








      Amortization of completed technology

      3,935


      0.09


      3,808


      0.08

      Amortization of other intangible assets

      7,113


      0.15


      8,376


      0.18

      Transformation costs(1)

      1,642


      0.04


      8,229


      0.18

      Restructuring charges

      2,565


      0.06


      4,011


      0.09

      Impairment of goodwill and intangible assets(2)

      149,083


      3.24


      —


      —

      Merger and acquisition costs(3)

      2,188


      0.05


      2,258


      0.05

      Non-recurring other income(4)

      (3,858)


      (0.08)


      (2,130)


      (0.05)

      Tax adjustments(5)

      —


      —


      7,300


      0.16

      Tax effect of adjustments

      1,901


      0.04


      1,106


      0.02

      Other adjustments

      26


      0.00


      (9)


      0.00

      Non-GAAP adjusted net income from continuing
      operations

      $         2,384


      $           0.05


      $       6,086


      $           0.13

      Stock-based compensation, pre-tax

      10,130


      0.22


      12,904


      0.28

      Tax rate

      13 %


      —


      17 %


      —

      Stock-based compensation, net of tax

      8,813


      0.19


      10,710


      0.23

      Non-GAAP adjusted net income excluding stock-based
      compensation - continuing operations

      $       11,197


      $           0.24


      $     16,796


      $           0.37









      Shares used in computing non-GAAP diluted net
      income per share



      45,995




      45,658



      (*)

      See footnote (1) on Page 1.

      (1)

      Transformation costs represent non-recurring expenses for strategic projects with anticipated long-term benefits to the Company focused on cost reduction and productivity improvement that do not meet the definition of restructuring charges. These costs are directed at simplifying, standardizing, streamlining, and optimizing the Company's operations, processes and systems to permanently alter the Company's operations for the long term. For a project to be considered transformational, successful completion of the project must be expected to bring long-term material benefits to the organization and involve significant changes to process and/or underlying technology. Transformation costs primarily relate to one time asset write downs associated with changes in technology, one time inventory write downs relating to restructuring actions, and third-party consulting costs associated with process and systems re-design.

      (2)

      Represents a non-cash goodwill impairment charge recognized in the second quarter of fiscal 2026 as a result of the Company's quantitative goodwill impairment analysis as of March 31, 2026, including $112.4 million for the Multiomics reporting unit and $36.6 million for the Sample Management Solutions reporting unit.

      (3)

      Includes expenses related to governance-related matters.

      (4)

      The Company recognized $3.9 million non-cash gain from the settlement of the pre-existing contractual relationship with UK Biocentre Limited in the second quarter of fiscal 2026. The Company received $2.1 million of cash proceeds from a cost method investment which had no cost basis in the second quarter of fiscal 2025. These are non-recurring and non-operational gains.

      (5)

      Tax adjustments for the three and six months ended March 31, 2025 are primarily driven by $6.4 million of tax expenses related to a one-time repatriation of historical earnings from China.


      Quarter Ended


      Six Months Ended

      Dollars in thousands

      March 31,
      2026


      December 31,
      2025


      March 31,
      2025
      (*)


      March 31,
      2026


      March 31,
      2025
      (*)

      GAAP net loss

      $   (160,798)


      $    (15,432)


      $     (47,661)


      $   (176,230)


      $     (58,653)

      Less: Loss from discontinued operations

      (3,777)


      (10,242)


      (27,871)


      (14,019)


      (31,790)

      GAAP net loss from continuing operations

      (157,021)


      (5,190)


      (19,790)


      (162,211)


      (26,863)

      Adjustments:










      Interest income, net

      (4,387)


      (5,098)


      (4,489)


      (9,485)


      (8,787)

      Income tax expense

      (323)


      3,130


      7,243


      2,807


      11,117

      Depreciation

      8,338


      8,207


      7,818


      16,545


      15,297

      Amortization of completed technology

      2,076


      1,860


      2,308


      3,935


      3,808

      Amortization of other intangible assets

      3,563


      3,551


      3,803


      7,113


      8,376

      Earnings before interest, taxes, depreciation
      and amortization - Continuing operations

      $   (147,754)


      $       6,460


      $       (3,107)


      $   (141,296)


      $        2,948




      Quarter Ended


      Six Months Ended

      Dollars in thousands

      March 31,
      2026


      December 31,
      2025


      March 31,
      2025
      (*)


      March 31,
      2026


      March 31,
      2025
      (*)

      Earnings before interest, taxes, depreciation
      and amortization - Continuing operations

      $   (147,754)


      $       6,460


      $       (3,107)


      $   (141,296)


      $        2,948

      Adjustments:










      Stock-based compensation

      6,268


      3,862


      8,031


      10,130


      12,904

      Restructuring charges

      1,422


      1,143


      3,580


      2,565


      4,011

      Impairment of goodwill and intangible
      assets(1)

      149,083


      13


      —


      149,083


      —

      Merger and acquisition costs(2)

      2,175


      1,202


      688


      2,188


      2,258

      Transformation costs(3)

      440


      12


      5,183


      1,642


      8,229

      Non-recurring other income(4)

      (3,858)


      —


      (2,130)


      (3,858)


      (2,130)

      Adjusted earnings before interest, taxes,
      depreciation and amortization - Continuing
      operations

      $        7,776


      $     12,692


      $      12,245


      $      20,454


      $      28,220



      (*)

      See footnote (1) on Page 1.

      (1)

      Represents a non-cash goodwill impairment charge recognized in the second quarter of fiscal 2026 as a result of the Company's quantitative goodwill impairment analysis as of March 31, 2026, including $112.4 million for the Multiomics reporting unit and $36.6 million for the Sample Management Solutions reporting unit.

      (2)

      Includes expenses related to governance-related matters.

      (3)

      Transformation costs represent non-recurring expenses for strategic projects with anticipated long-term benefits to the Company focused on cost reduction and productivity improvement that do not meet the definition of restructuring charges. These costs are directed at simplifying, standardizing, streamlining, and optimizing the Company's operations, processes and systems to permanently alter the Company's operations for the long term. For a project to be considered transformational, successful completion of the project must be expected to bring long-term material benefits to the organization and involve significant changes to process and/or underlying technology. Transformation costs primarily relate to one time asset write downs associated with changes in technology, one time inventory write downs relating to restructuring actions, and third-party consulting costs associated with process and systems re-design.

      (4)

      The Company recognized $3.9 million non-cash gain from the settlement of the pre-existing contractual relationship with UK Biocentre Limited in the second quarter of fiscal 2026. The Company received $2.1 million of cash proceeds from a cost method investment which had no cost basis in the second quarter of fiscal 2025. These are non-recurring and non-operational gains.


      Quarter Ended

      Dollars in thousands

      March 31, 2026


      December 31, 2025


      March 31, 2025(*)

      GAAP gross profit

      $   62,035


      42.8 %


      $   63,706


      42.9 %


      $   62,783


      43.8 %

      Adjustments:












      Amortization of completed
      technology

      2,076


      1.4 %


      1,860


      1.3 %


      2,308


      1.6 %

      Other Adjustments

      —


      — %


      —


      — %


      (9)


      (0.0 %)

      Non-GAAP adjusted gross profit

      $   64,111


      44.3 %


      $   65,566


      44.1 %


      $   65,082


      45.4 %


      Six Months Ended

      Dollars in thousands

      March 31, 2026



      March 31, 2025(*)

      GAAP gross profit

      $         125,741


      42.9 %



      $         131,602


      45.3 %

      Adjustments:









      Amortization of completed technology

      3,935


      1.3 %



      3,808


      1.3 %

      Transformation costs(1)

      —


      — %



      52


      0.0 %

      Non-GAAP adjusted gross profit

      $         129,676


      44.2 %



      $         135,462


      46.6 %



      (*)

      See footnote (1) on Page 1.

      (1)

      Transformation costs represent non-recurring expenses for strategic projects with anticipated long-term benefits to the Company focused on cost reduction and productivity improvement that do not meet the definition of restructuring charges. These costs are directed at simplifying, standardizing, streamlining, and optimizing the Company's operations, processes and systems to permanently alter the Company's operations for the long term. For a project to be considered transformational, successful completion of the project must be expected to bring long-term material benefits to the organization and involve significant changes to process and/or underlying technology. Transformation costs primarily relate to one time asset write downs associated with changes in technology, one time inventory write downs relating to restructuring actions, and third-party consulting costs associated with process and systems re-design.


      Sample Management Solutions


      Multiomics


      Quarter Ended


      Quarter Ended

      Dollars in thousands

      March 31,
      2026


      December 31,
      2025


      March 31,
      2025
      (*)


      March 31,
      2026


      December 31,
      2025


      March 31,
      2025
      (*)

      GAAP gross profit

      $ 37,084


      45.7 %


      $ 35,785


      43.9 %


      $ 36,147


      45.3 %


      $ 24,951


      39.2 %


      $ 27,921


      41.5 %


      $ 26,636


      41.9 %

      Adjustments:
























      Amortization of
      completed technology

      1,389


      1.7 %


      1,177


      1.4 %


      1,449


      1.8 %


      687


      1.1 %


      683


      1.0 %


      859


      1.4 %

      Other Adjustments

      —


      — %


      —


      — %


      (9)


      (0.0 %)


      —


      — %


      —


      — %


      —


      — %

      Non-GAAP adjusted
      gross profit

      $ 38,473


      47.4 %


      $ 36,962


      45.4 %


      $ 37,587


      47.1 %


      $ 25,638


      40.2 %


      $ 28,604


      42.6 %


      $ 27,495


      43.3 %


      Segment Total


      Quarter Ended

      Dollars in thousands

      March 31,
      2026


      December 31,
      2025


      March 31,
      2025
      (*)

      GAAP gross profit

      $        62,035


      42.8 %


      $        63,706


      42.9 %


      $        62,783


      43.8 %

      Adjustments:












      Amortization of
      completed
      technology

      2,076


      1.4 %


      1,860


      1.3 %


      2,308


      1.6 %

      Other Adjustments

      —


      — %


      —


      — %


      (9)


      (0.0 %)

      Non-GAAP adjusted
      gross profit

      $        64,111


      44.3 %


      $        65,566


      44.1 %


      $        65,082


      45.4 %


      Sample Management Solutions


      Multiomics


      Six Months Ended


      Six Months Ended

      Dollars in thousands

      March 31, 2026



      March 31, 2025(*)


      March 31, 2026



      March 31, 2025(*)

      GAAP gross profit

      $    72,867


      44.8 %



      $    75,290


      46.8 %


      $    52,874


      40.4 %



      $    56,312


      43.4 %

      Adjustments:


















      Amortization of completed
      technology

      2,565


      1.6 %



      2,088


      1.3 %


      1,370


      1.0 %



      1,720


      1.3 %

      Transformation costs(1)

      —


      — %



      52


      0.0 %


      —


      — %



      —


      — %

      Non-GAAP adjusted gross profit

      $    75,432


      46.4 %



      $    77,430


      48.1 %


      $    54,244


      41.4 %



      $    58,032


      44.7 %


      Segment Total


      Six Months Ended

      Dollars in thousands

      March 31, 2026



      March 31, 2025(*)

      GAAP gross profit

      $         125,741


      42.9 %



      $         131,602


      45.3 %

      Adjustments:









      Amortization of completed technology

      3,935


      1.3 %



      3,808


      1.3 %

      Transformation costs(1)

      —


      — %



      52


      0.0 %

      Non-GAAP adjusted gross profit

      $         129,676


      44.2 %



      $         135,462


      46.6 %



      (*)

      See footnote (1) on Page 1.

      (1)

      Transformation costs represent non-recurring expenses for strategic projects with anticipated long-term benefits to the Company focused on cost reduction and productivity improvement that do not meet the definition of restructuring charges. These costs are directed at simplifying, standardizing, streamlining, and optimizing the Company's operations, processes and systems to permanently alter the Company's operations for the long term. For a project to be considered transformational, successful completion of the project must be expected to bring long-term material benefits to the organization and involve significant changes to process and/or underlying technology. Transformation costs primarily relate to one time asset write downs associated with changes in technology, one time inventory write downs relating to restructuring actions, and third-party consulting costs associated with process and systems re-design.


      Sample Management Solutions


      Multiomics


      Quarter Ended


      Quarter Ended

      Dollars in thousands

      March 31,
      2026


      December 31,
      2025


      March 31,
      2025
      (*)


      March 31,
      2026


      December 31,
      2025


      March 31,
      2025
      (*)

      GAAP operating income (loss)

      $     1,668


      $     3,731


      $   (1,236)


      $  (10,759)


      $   (5,044)


      $   (6,372)

      Adjustments:












      Amortization of completed technology

      1,389


      1,177


      1,449


      687


      683


      859

      Transformation costs(1)

      55


      57


      2,606


      —


      —


      —

      Other adjustments

      3


      12


      (10)


      5


      —


      (23)

      Non-GAAP adjusted operating income
      (loss)

      $     3,115


      $     4,977


      $     2,809


      $  (10,067)


      $   (4,361)


      $   (5,536)


      Total Segments


      Corporate


      Total


      Quarter Ended


      Quarter Ended


      Quarter Ended

      Dollars in thousands

      March
      31,

      2026


      December
      31,

      2025


      March
      31,
      2025
      (*)


      March
      31,

      2026


      December
      31,

      2025


      March
      31,
      2025
      (*)


      March
      31,

      2026


      December
      31,

      2025


      March
      31,
      2025
      (*)

      GAAP operating loss

      $   (9,091)


      $   (1,313)


      $ (7,608)


      $ (156,699)


      $   (5,924)


      $  (10,586)


      $ (165,790)


      $ (7,237)


      $  (18,194)

      Adjustments:


















      Amortization of
      completed technology

      2,076


      1,860


      2,308


      —


      —


      —


      2,076


      1,860


      2,308

      Amortization of other
      intangible assets

      —


      —


      —


      3,563


      3,551


      3,803


      3,563


      3,551


      3,803

      Transformation costs(1)

      55


      57


      2,606


      385


      1,145


      2,577


      440


      1,202


      5,183

      Restructuring charges

      —


      —


      —


      1,422


      1,143


      3,580


      1,422


      1,143


      3,580

      Impairment of goodwill
      and intangible assets(2)

      —


      —


      —


      149,083


      —


      —


      149,083


      —


      —

      Merger and acquisition
      costs(3)

      —


      —


      —


      2,175


      13


      688


      2,175


      13


      688

      Other adjustments

      8


      12


      (33)


      —


      —


      —


      8


      12


      (33)

      Non-GAAP adjusted
      operating income (loss)

      $   (6,952)


      $       616


      $ (2,727)


      $      (71)


      $        (72)


      $          62


      $     (7,023)


      $     544


      $    (2,665)


      Sample Management Solutions


      Multiomics


      Six Months Ended


      Six Months Ended

      Dollars in thousands

      March 31,
      2026


      March 31,
      2025
      (*)


      March 31,
      2026


      March 31,
      2025
      (*)

      GAAP operating income (loss)

      $            5,398


      $            2,786


      $         (15,802)


      $          (9,566)

      Adjustments:








      Amortization of completed technology

      2,565


      2,088


      1,370


      1,720

      Transformation costs(1)

      112


      2,709


      —


      —

      Other adjustments

      17


      (3)


      5


      3

      Non-GAAP adjusted operating income
      (loss)

      $            8,092


      $            7,580


      $         (14,427)


      $          (7,843)


      Total Segments


      Corporate


      Total


      Six Months Ended


      Six Months Ended


      Six Months Ended

      Dollars in thousands

      March 31,
      2026


      March 31,
      2025
      (*)


      March 31,
      2026


      March 31,
      2025
      (*)


      March 31,
      2026


      March 31,
      2025
      (*)

      GAAP operating loss

      $  (10,404)


      $   (6,780)


      $ (162,623)


      $  (20,115)


      $ (173,027)


      $  (26,895)

      Adjustments:












      Amortization of completed technology

      3,935


      3,808


      —


      —


      3,935


      3,808

      Amortization of other intangible
      assets

      —


      —


      7,113


      8,376


      7,113


      8,376

      Transformation costs(1)

      112


      2,709


      1,530


      5,520


      1,642


      8,229

      Restructuring charges

      —


      —


      2,565


      4,011


      2,565


      4,011

      Impairment of goodwill and intangible
      assets(2)

      —


      —


      149,083


      —


      149,083


      —

      Merger and acquisition costs(3)

      —


      —


      2,188


      2,258


      2,188


      2,258

      Other adjustments

      22


      —


      —


      —


      22


      —

      Non-GAAP adjusted operating income
      (loss)

      $    (6,335)


      $       (263)


      $        (144)


      $          50


      $     (6,479)


      $       (213)



      (*)

      See footnote (1) on Page 1.

      (1)

      Transformation costs represent non-recurring expenses for strategic projects with anticipated long-term benefits to the Company focused on cost reduction and productivity improvement that do not meet the definition of restructuring charges. These costs are directed at simplifying, standardizing, streamlining, and optimizing the Company's operations, processes and systems to permanently alter the Company's operations for the long term. For a project to be considered transformational, successful completion of the project must be expected to bring long-term material benefits to the organization and involve significant changes to process and/or underlying technology. Transformation costs primarily relate to one time asset write downs associated with changes in technology, one time inventory write downs relating to restructuring actions, and third-party consulting costs associated with process and systems re-design.

      (2)

      Represents non-cash goodwill impairment charges recognized in the second quarter of fiscal 2026 as a result of the Company's annual and interim impairment assessment, including $112.4 million for the Multiomics reporting unit and $36.6 million for the Sample Management Solutions reporting unit.

      (3)

      Includes expenses related to governance-related matters.


      Sample Management Solutions


      Multiomics


      Azenta Total


      Quarter Ended


      Quarter Ended


      Quarter Ended

      Dollars in millions

      March 31,
      2026


      March 31,
      2025


      Change


      March 31,
      2026


      March 31,
      2025


      Change


      March 31,
      2026


      March 31,
      2025


      Change

      Revenue

      $      81


      $      80


      2 %


      $      64


      $      64


      0 %


      $     145


      $     143


      1 %

      Acquisitions

      (1)


      —


      (2) %


      —


      —


      — %


      (1)


      —


      (1) %

      Currency
      exchange rates

      (2)


      —


      (3) %


      (2)


      —


      (3) %


      (4)


      —


      (3) %

      Organic revenue

      $      78


      $      80


      (3) %


      $      62


      $      64


      (2) %


      $     140


      $     143


      (3) %




      Sample Management Solutions


      Multiomics


      Azenta Total


      Six Months Ended


      Six Months Ended


      Six Months Ended

      Dollars in millions

      March 31,
      2026


      March 31,
      2025


      Change


      March 31,
      2026


      March 31,
      2025


      Change


      March 31,
      2026


      March 31,
      2025


      Change

      Revenue

      $     163


      $     161


      1 %


      $     131


      $     130


      1 %


      $     293


      $     291


      1 %

      Acquisitions

      (1)


      —


      (1) %


      —


      —


      — %


      (1)


      —


      (0 %)

      Currency
      exchange rates

      (4)


      —


      (3) %


      (3)


      —


      (2) %


      (7)


      —


      (2) %

      Organic revenue

      $     157


      $     161


      (2) %


      $     128


      $     130


      (1) %


      $     285


      $     291


      (2) %

      SOURCE Azenta

      Modal title

      Also from this source

      Azenta Reports Fourth Quarter and Full Year Results for Fiscal 2026, Ended September 30, 2026.

      Azenta Reports Fourth Quarter and Full Year Results for Fiscal 2026, Ended September 30, 2026.

      Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the fourth quarter and fiscal year ended September 30, 2026. B Medical Systems is...

      Azenta Announces Strategic Investments to Advance the Next Generation of GENEWIZ Gene Synthesis Capabilities

      Azenta Announces Strategic Investments to Advance the Next Generation of GENEWIZ Gene Synthesis Capabilities

      Azenta, Inc. (Nasdaq: AZTA) today announced strategic investments to advance the next phase of growth for its GENEWIZ business. Building on its...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Earnings

      Earnings

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.